» Articles » PMID: 12709323

Fungicidal Synergism of Fluconazole and Cyclosporine in Candida Albicans is Not Dependent on Multidrug Efflux Transporters Encoded by the CDR1, CDR2, CaMDR1, and FLU1 Genes

Overview
Specialty Pharmacology
Date 2003 Apr 24
PMID 12709323
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The combination of fluconazole (FLC) and cyclosporine (CY) is fungicidal in FLC-susceptible C. albicans (O. Marchetti, P. Moreillon, M. P. Glauser, J. Bille, and D. Sanglard, Antimicrob. Agents Chemother. 44:2373-2381, 2000). The mechanism of this synergism is unknown. CY has several cellular targets including multidrug efflux transporters. The hypothesis that CY might inhibit FLC efflux was investigated by comparing the effect of FLC-CY in FLC-susceptible parent CAF2-1 (FLC MIC, 0.25 mg/liter) and in FLC-hypersusceptible mutant DSY1024 (FLC MIC, 0.03 mg/liter), in which the CDR1, CDR2, CaMDR1, and FLU1 transporter genes have been selectively deleted. We postulated that a loss of the fungicidal effect of FLC-CY in DSY1024 would confirm the roles of these efflux pumps. Time-kill curve studies showed a more potent fungistatic effect of FLC (P = 0.05 at 48 h with an inoculum of 10(3) CFU/ml) and a more rapid fungicidal effect of FLC-CY (P = 0.05 at 24 h with an inoculum of 10(3) CFU/ml) in the FLC-hypersusceptible mutant compared to those in the parent. Rats with experimental endocarditis were treated for 2 or 5 days with high-dose FLC, high-dose CY, or both drugs combined. FLC monotherapy for 5 days was more effective against the hypersusceptible mutant than against the parent. However, the addition of CY to FLC still conferred a therapeutic advantage in animals infected with mutant DSY1024, as indicated by better survival (P = 0.04 versus the results obtained with FLC) and sterilization of valves and kidneys after a very short (2-day) treatment (P = 0.009 and 0.002, respectively, versus the results obtained with FLC). Both in vitro and in vivo experiments consistently showed that the deletion of the four membrane transporters in DSY1024 did not result in loss of the fungicidal effect of FLC-CY. Yet, the accelerated killing in the mutant suggested a "dual-hit" mechanism involving FLC hypersusceptibility due to the efflux pump elimination and fungicidal activity conferred by CY. Thus, inhibition of multidrug efflux transporters encoded by CDR1, CDR2, CaMDR1, and FLU1 genes is not responsible for the fungicidal synergism of FLC-CY. Other cellular targets must be considered.

Citing Articles

Mechanism and bioinformatics analysis of the effect of berberine-enhanced fluconazole against drug-resistant Candida albicans.

Wu S, Jia W, Lu Y, Jiang H, Huang C, Tang S BMC Microbiol. 2024; 24(1):196.

PMID: 38849761 PMC: 11157861. DOI: 10.1186/s12866-024-03334-0.


Myriocin enhances the antifungal activity of fluconazole by blocking the membrane localization of the efflux pump Cdr1.

Wang H, Ji Z, Feng Y, Yan T, Cao Y, Lu H Front Pharmacol. 2023; 13:1101553.

PMID: 36618949 PMC: 9815617. DOI: 10.3389/fphar.2022.1101553.


Eucalyptal D Enhances the Antifungal Effect of Fluconazole on Fluconazole-Resistant by Competitively Inhibiting Efflux Pump.

Xu J, Liu R, Sun F, An L, Shang Z, Kong L Front Cell Infect Microbiol. 2019; 9:211.

PMID: 31281800 PMC: 6595430. DOI: 10.3389/fcimb.2019.00211.


The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms.

Jia W, Zhang H, Li C, Li G, Liu X, Wei J BMC Microbiol. 2016; 16(1):113.

PMID: 27316338 PMC: 4912705. DOI: 10.1186/s12866-016-0728-1.


Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.

Sanglard D, Coste A Antimicrob Agents Chemother. 2015; 60(1):229-38.

PMID: 26482310 PMC: 4704203. DOI: 10.1128/AAC.02157-15.


References
1.
List A, Spier C, Greer J, Wolff S, Hutter J, Dorr R . Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol. 1993; 11(9):1652-60. DOI: 10.1200/JCO.1993.11.9.1652. View

2.
Fonzi W, Irwin M . Isogenic strain construction and gene mapping in Candida albicans. Genetics. 1993; 134(3):717-28. PMC: 1205510. DOI: 10.1093/genetics/134.3.717. View

3.
Sanglard D, Kuchler K, Ischer F, Pagani J, Monod M, Bille J . Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother. 1995; 39(11):2378-86. PMC: 162951. DOI: 10.1128/AAC.39.11.2378. View

4.
Nguyen M, Peacock Jr J, Morris A, Tanner D, Nguyen M, Snydman D . The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996; 100(6):617-23. DOI: 10.1016/s0002-9343(95)00010-0. View

5.
Marks A . Cellular functions of immunophilins. Physiol Rev. 1996; 76(3):631-49. DOI: 10.1152/physrev.1996.76.3.631. View